Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/20/2018 09/21/2018 09/24/2018 09/25/2018 09/26/2018 Date
5572(c) 5670(c) 5652(c) 5793(c) 5871 Last
2 889 575 4 502 270 1 282 646 2 153 904 811 980 Volume
-0.52% +1.76% -0.32% +2.49% +1.35% Change
More quotes
Financials (USD)
Sales 2018 22 396 M
EBIT 2018 5 404 M
Net income 2018 2 284 M
Debt 2018 14 738 M
Yield 2018 3,58%
Sales 2019 23 884 M
EBIT 2019 6 161 M
Net income 2019 2 952 M
Debt 2019 15 348 M
Yield 2019 3,62%
P/E ratio 2018 41,58
P/E ratio 2019 34,98
EV / Sales2018 4,96x
EV / Sales2019 4,67x
Capitalization 96 274 M
More Financials
Company
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products.The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases.Its... 
Sector
Pharmaceuticals
Calendar
11/08Earnings Release
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
12:19pASTRAZENECA : Entasis raises $75M in IPO
AQ
01:15aMHEALTH APP MARKET EXPECTED TO GROW : This market research report on MHealth Ap..
AQ
09/25ASTRAZENECA : Positive Data Bolsters Case For AstraZeneca's Imfinzi -- Update
DJ
09/25ASTRAZENECA : Immunotherapy drug cuts lung cancer deaths by almost a third
AQ
09/25ASTRAZENECA : Data Show Cancer Drug Imfinzi Reduces Death Risk
DJ
09/25ASTRAZENECA : Imfinzi is the first immunotherapy to demonstrate significant over..
PU
09/25ASTRAZENECA : IMFINZI® (durvalumab) is the First Immunotherapy to Demonstrate Si..
BU
09/25OVERALL SURVIVAL DATA FOR IMFINZI : Stage III NSCLC
AQ
09/25ASTRAZENECA : Bydureon receives positive EU CHMP opinion for EXSCEL cardiovascul..
AQ
09/25ASTRAZENECA : Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2018-2019 Flu Se..
BU
More news
Sector news : Pharmaceuticals - NEC
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/25EUROPE : Oil boost and Italy budget hopes support European shares
RE
09/25NOVARTIS : to Cut 2,000 Jobs Amid Revamp -- 2nd Update
DJ
09/25NOVARTIS : Cuts Over 2,000 Jobs in Switzerland as It Continues to Refocus -- Upd..
DJ
09/25NOVARTIS : Plans to Cut Over 2,000 Jobs in Switzerland
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on ASTRAZENECA 
ASTRAZENECA - 2016
A rally could take place
BUY
More Strategies
Latest Tweets
07:29aAstraZeneca plots China robot offensive to counter price cuts  
09/25Parents, if you've been holding out for FluMist for your needle-averse child,..
6
09/25AstraZeneca buoyed as Imfinzi cuts lung cancer deaths by a third  
09/25Data Confirms AstraZeneca's Imfinzi Provides Unprecedented Improvement in Pro.. 
09/25$AZN: AstraZeneca presents data on overall survival in the Phase III PACIFIC .. 
More tweets
Qtime:147
News from SeekingAlpha
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/25ARVINAS IPO : 40% Is Cash, But Research Is At An Early Stage 
09/25AstraZeneca's Imfinzi improved survival in late-stage lung cancer study; shar.. 
09/25AstraZeneca ships FLUMIST QUADRIVALENT vaccine in the US 
09/25European advisory group backs inclusion of CV data in labeling of AstraZeneca.. 
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 77,4 $
Spread / Average Target 1,4%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA10.72%96 274
JOHNSON & JOHNSON2.26%371 937
PFIZER20.90%256 702
NOVARTIS-0.63%219 947
ROCHE HOLDING LTD.-4.20%211 344
MERCK AND COMPANY25.79%187 895